Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
NTHI Heads into Wednesday with a Rare Biotech Convergence: Brain-Cancer Data, Tight Float, and Analyst Targets
DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...
24-7 Market News
More News
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SHELTON, Conn., Aug. 11, 2026 Initiated activities to resume enrollment in a limited number...
PR Newswire
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 PR Newswire SHELTON, Conn., Aug. 4, 2026 Company to hold a conference call at 8AM ET on August 11, 2026 to review...
PR Newswire
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...
PR Newswire
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR...
PR Newswire
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...
PR Newswire
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...
PR Newswire
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks

Advertisement|Remove ads.